1 |
Koizumi, F., Kanzawa, F., Ueda, Y., Koh, Y., Tsukiyama, S., Taguchi, F., Tamura, T., Saijo, N. and Nishio, K. (2004) Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. Int. J. Cancer 108, 464-472.
DOI
ScienceOn
|
2 |
Barth, S. W., Briviba, K., Watzl, B., Jager, N., Marko, D. and Esselen, M. (2010) In vivo bioassay to detect irinotecan-stabilized DNA/topoisomerase I complexes in rats. Biotechnol. J. 5, 321-327.
DOI
ScienceOn
|
3 |
Choi, H. G., Jung, J. H., Ryu, J. M., Yoon, S. J., Oh, Y. K. and Kim, C. K. (1998) Development of in-situ gelling and mucoadhesive acetaminophen liquid suppository. Int. J. Pharm. 165, 33-44.
DOI
ScienceOn
|
4 |
Hind, D., Tappenden, P., Tumur, I., Eggington, S., Sutcliffe, P. and Ryan, A. (2008) The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol. Assess. 12, iii-ix, xi-162.
|
5 |
Hirasawa, A., Zama, T., Akahane, T., Nomura, H., Kataoka, F., Saito, K., Okubo, K., Tominaga, E., Makita, K., Susumu, N., Kosaki, K., Tanigawara, Y. and Aoki, D. (2013) Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patients. J. Hum. Genet. 58, 825
DOI
|
6 |
Kanzawa, F., Koizumi, F., Koh, Y., Nakamura, T., Tatsumi, Y., Fukumoto, H., Saijo, N., Yoshioka, T. and Nishio, K. (2001) In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction. Clin. Cancer Res. 7, 202-209.
|
7 |
Kunimoto, T., Nitta, K., Tanaka, T., Uehara, N., Baba, H., Takeuchi, M., Yokokura, T., Sawada, S., Miyasaka, T. and Mutai, M. (1987) Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res. 47, 5944-5947.
|
8 |
Negi, L. M., Tariq, M. and Talegaonkar, S. (2013) Nano scale self-emulsifying oil based carrier system for improved oral bioavailability of camptothecin derivative by P-Glycoprotein modulation. Colloids Surf. B. Biointerfaces 111C, 346-353.
|
9 |
Sandler, A. (2002) Irinotecan therapy for small-cell lung cancer. Oncology (Williston Park) 16, 419-425, 428, 433
|
10 |
Tsuruo, T., Matsuzaki, T., Matsushita, M., Saito, H. and Yokokura, T. (1988) Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother. Pharmacol. 21, 71-74.
|
11 |
Takatori, E., Shoji, T., Miura, Y., Takeuchi, S., Yoshizaki, A. and Sugiyama, T. (2013) Recurrent cervical cancer in a patient who was compound heterozygous for UGT1A1*6 and UGT1A1*28 presenting with serious adverse events during irinotecan hydrochloride/nedaplatin therapy. J. Obstet. Gynaecol. Res. 39, 1354-1358.
DOI
ScienceOn
|
12 |
Sawada, S., Okajima, S., Aiyama, R., Nokata, K., Furuta, T., Yokokura, T., Sugino, E., Yamaguchi, K. and Miyasaka, T. (1991) Synthesis and antitumor activity of 20(S)-camptothecin derivatives: carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin. Chem. Pharm. Bull. 39, 1446-1450.
DOI
ScienceOn
|
13 |
Takahashi, R., Sato, T., Klinman, D. M., Shimosato, T., Kaneko, T. and Ishigatsubo, Y. (2013) Suppressive oligodeoxynucleotides synergistically enhance antiproliferative effects of anticancer drugs in A549 human lung cancer cells. Int. J. Oncol. 42, 429-436.
DOI
|
14 |
Yong, C. S., Oh, Y. K., Jung, S. H., Rhee, J. D., Kim, H. D., Kim, C. K. and Choi, H. G. (2004) Preparation of ibuprofen-loaded liquid suppository using eutectic mixture system with menthol. Eur. J. Pharm. Sci. 23, 347-353.
DOI
ScienceOn
|